Literature DB >> 11330838

Apoptosis, growth arrest and suppression of invasiveness by CRE-decoy oligonucleotide in ovarian cancer cells: protein kinase A downregulation and cytoplasmic export of CRE-binding proteins.

O Alper1, E S Bergmann-Leitner, S Abrams, Y S Cho-Chung.   

Abstract

The CRE (cyclic AMP response element)-transcription factor complex plays a critical role in response to hormonal signals for cell proliferation, differentiation, and apoptosis. We have reported previously that the CRE-transcription factor decoy oligonucleotide specifically slows tumor cell proliferation and inhibits CRE- and Ap-1-directed transcription in vivo (Park et al., 1999). We have investigated the effect of inhibiting CRE-directed transcription on ovarian cancer cell growth. Here, we report that CRE-decoy oligonucleotide treatment results in the inhibition of cell growth and a marked reduction in the expression of the regulatory and catalytic subunits of protein kinase A and the type I and type II protein kinase A holoenzymes. Growth inhibition was accompanied by changes in cell morphology, appearance of apoptotic nuclei, and DNA fragmentation. In addition, MMP-9 (matrix methalloproteinase-9) activity was markedly reduced in CRE-decoy treated cells. Indirect immunofluorescence revealed that CRE-decoy oligonucleotide treatment promoted export of the CRE-binding protein, CREB, from the nucleus to the cytoplasm, while importing the catalytic subunit of protein kinase A from the cytoplasm to the nucleus. The results indicate that the decoy oligonucleotide, by binding specifically to CRE-transcription factors, interferes with CRE-directed transcription in vivo. These results show a critical role for CRE-directed transcription in ovarian cancer cell growth. Thus, the CRE-decoy oligonucleotide may provide a powerful means to combat ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11330838     DOI: 10.1023/a:1007205205131

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  33 in total

1.  Novel function of the regulatory subunit of protein kinase A: regulation of cytochrome c oxidase activity and cytochrome c release.

Authors:  W L Yang; L Iacono; W M Tang; K V Chin
Journal:  Biochemistry       Date:  1998-10-06       Impact factor: 3.162

Review 2.  cAMP-dependent protein kinase: role in normal and malignant growth.

Authors:  Y S Cho-Chung; S Pepe; T Clair; A Budillon; M Nesterova
Journal:  Crit Rev Oncol Hematol       Date:  1995-11       Impact factor: 6.312

Review 3.  Antisense-protein kinase A: a single-gene-based therapeutic approach.

Authors:  Y S Cho-Chung; M Nesterova; A Kondrashin; K Noguchi; R Srivastava; S Pepe
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1997-06

Review 4.  Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases.

Authors:  P Borden; R A Heller
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1997       Impact factor: 1.807

Review 5.  Phosphorylation-dephosphorylation of enzymes.

Authors:  E G Krebs; J A Beavo
Journal:  Annu Rev Biochem       Date:  1979       Impact factor: 23.643

6.  Programmed cell death (apoptosis) is induced rapidly and with positive cooperativity by activation of cyclic adenosine monophosphate-kinase I in a myeloid leukemia cell line.

Authors:  M Lanotte; J B Riviere; S Hermouet; G Houge; O K Vintermyr; B T Gjertsen; S O Døskeland
Journal:  J Cell Physiol       Date:  1991-01       Impact factor: 6.384

Review 7.  Cyclic AMP second messenger systems.

Authors:  G S McKnight
Journal:  Curr Opin Cell Biol       Date:  1991-04       Impact factor: 8.382

8.  A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription.

Authors:  J L Rutter; T I Mitchell; G Butticè; J Meyers; J F Gusella; L J Ozelius; C E Brinckerhoff
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

9.  A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth.

Authors:  M Nesterova; Y S Cho-Chung
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

10.  A cluster of phosphorylation sites on the cyclic AMP-regulated nuclear factor CREB predicted by its sequence.

Authors:  G A Gonzalez; K K Yamamoto; W H Fischer; D Karr; P Menzel; W Biggs; W W Vale; M R Montminy
Journal:  Nature       Date:  1989-02-23       Impact factor: 49.962

View more
  12 in total

Review 1.  Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer.

Authors:  Seyed Mohammad Ali Hosseini Rad; Lida Langroudi; Fatemeh Kouhkan; Laleh Yazdani; Alireza Nouri Koupaee; Sara Asgharpour; Zahra Shojaei; Taravat Bamdad; Ehsan Arefian
Journal:  Tumour Biol       Date:  2015-04-04

2.  Relaxin stimulates multiple signaling pathways: activation of cAMP, PI3K, and PKCzeta in THP-1 cells.

Authors:  Carmen W Dessauer; Bao T Nguyen
Journal:  Ann N Y Acad Sci       Date:  2005-05       Impact factor: 5.691

3.  A genomic-scale view of the cAMP response element-enhancer decoy: a tumor target-based genetic tool.

Authors:  Yee Sook Cho; Meyoung-Kon Kim; Chris Cheadle; Catherine Neary; Yun Gyu Park; Kevin G Becker; Yoon S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-18       Impact factor: 11.205

4.  Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells.

Authors:  Christopher D Suarez; Xuehong Deng; Chang-Deng Hu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

5.  Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy.

Authors:  Seyed Mohammad Ali Hosseini Rad; Taravat Bamdad; Majid Sadeghizadeh; Ehsan Arefian; Majid Lotfinia; Milad Ghanipour
Journal:  Tumour Biol       Date:  2014-12-03

Review 6.  cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach.

Authors:  Muhammad Bilal Ahmed; Abdullah A A Alghamdi; Salman Ul Islam; Joon-Seok Lee; Young-Sup Lee
Journal:  Cells       Date:  2022-06-24       Impact factor: 7.666

7.  Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells.

Authors:  Zhi-Qiang Wang; Mamadou Keita; Magdalena Bachvarova; Stephane Gobeil; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

Review 8.  Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target.

Authors:  André Steven; Barbara Seliger
Journal:  Oncotarget       Date:  2016-06-07

Review 9.  What turns CREB on? And off? And why does it matter?

Authors:  André Steven; Michael Friedrich; Paul Jank; Nadine Heimer; Jan Budczies; Carsten Denkert; Barbara Seliger
Journal:  Cell Mol Life Sci       Date:  2020-04-28       Impact factor: 9.261

10.  Local translation and retrograde axonal transport of CREB regulates IL-6-induced nociceptive plasticity.

Authors:  Ohannes K Melemedjian; Dipti V Tillu; Jamie K Moy; Marina N Asiedu; Edward K Mandell; Sourav Ghosh; Gregory Dussor; Theodore J Price
Journal:  Mol Pain       Date:  2014-07-04       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.